Article Figures & Data
Figures
- Fig 1.
A 44-year-old man with squamous cell carcinoma of the nasopharynx. Axial T1 (A) and coronal STIR (B and C) sequences, with corresponding PET (D–F) and the fusion of both (G–I), in a patient with nasopharyngeal carcinoma. The neoplastic tissue (arrowheads) is easily identifiable in STIR sequences (B) in which the cystic component can be visualized (arrows). The T1-weighted sequences allow a good assessment of the fat planes. Metastatic lymph nodes (dotted arrows) can be assessed morphologically (C) and functionally (I). Notice the concordance of the cystic areas of the lesion with an area of lower 18F-FDG uptake as expected.
- Fig 2.
Scatterplots as visualization of the correlations demonstrating SUVmax values in PET/CT and PET/MR imaging for 18F-FDG-avid lymph node (A), lung (B), liver (C), and bone (D) lesions.
Tables
Patient Sex Age (yr) Histopathology Treatment Prior to PET/MRI Study 1 Male 53 Squamous cell carcinoma of the tongue Radiation therapy and chemotherapy 2 Male 46 Adenocarcinoma of the salivary gland Chemotherapy 3 Male 66 Squamous cell carcinoma of the tongue Radiation therapy and chemotherapy 4 Male 67 Squamous cell carcinoma of the oropharynx Radiation therapy and chemotherapy 5 Male 51 Adenocarcinoma of the salivary gland Chemotherapy 6 Male 63 Squamous cell carcinoma of the tongue and pharyngeal wall Radiation therapy and chemotherapy 7 Male 54 Squamous cell carcinoma of the tonsil No therapy 8 Female 49 Squamous cell carcinoma of the tongue Radiation therapy and chemotherapy 9 Male 66 Squamous cell carcinoma of the tonsil Radiation therapy and chemotherapy 10 Male 54 Squamous cell carcinoma of the tonsil Radiation therapy and chemotherapy 11 Male 57 Squamous cell carcinoma of the tongue Radiation therapy and chemotherapy 12 Male 42 Squamous cell carcinoma of the tongue No therapy 13 Male 54 Squamous cell carcinoma of the oropharynx Radiation therapy and chemotherapy 14 Male 44 Squamous cell carcinoma of the nasopharynx No therapy - Table 2:
Statistical analysis of differences and correlation between SUVmax from PET/CT and PET/MRI
Primary Tumor Lesions (n = 4) Lymph Node Lesions (n = 45) Distant Metastasis Lesions (n = 38) Spearman r 1.00 0.93 0.92 PET/CT 15.69 ± 8.61 5.42 ± 2.83 5.30 ± 2.56 PET/MRI 15.88 ± 5.01 7.10 ± 3.61 6.35 ± 2.92 Differencea 0.20 ± 3.97 1.67 ± 1.76 1.05 ± 1.42 P valueb .875 <.0001 <.0001 - Table 3:
Statistical analysis of differences and correlation between SUVmax from PET/CT and PET/MRI regarding the location of distant metastasis
Bone Lesions (n = 12) Liver Lesions (n = 9) Lung Lesions (n = 15) Spearman r 0.89 0.88 0.93 PET/CT 5.67 ± 2.14 5.92 ± 3.43 4.13 ± 1.41 PET/MRI 6.78 ± 3.28 6.83 ± 2.73 5.12 ± 2.07 Differencea 1.11 ± 1.96 0.91 ± 1.56 0.99 ± 0.88 P valueb .034 .098 .0006
Jump to section
Related Articles
Cited By...
- Diagnostic Accuracy of [18F]FDG PET/MRI in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Metaanalysis
- A Comparison of 18F-FDG-PET/MRI and 18F-FDG-PET/CT in the Cancer Staging of Locoregional Lymph Nodes
- 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients